The 1st randomized trial of a booster (3rd) shot in 10,000 people, placebo-controlled, shows 95.6% efficacy, with 5 cases (Pfizer vaccine) vs 109 in placebo group, Delta variant, broad benefit across age groups https://t.co/TQpF35d8Jk pic.twitter.com/3RkqvXNfsU

— Eric Topol (@EricTopol) October 21, 2021